ஆஸ்திரேலிய ஸ்டாக் பரிமாற்றம் தில்க்ஷ கோடரி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஆஸ்திரேலிய ஸ்டாக் பரிமாற்றம் தில்க்ஷ கோடரி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஆஸ்திரேலிய ஸ்டாக் பரிமாற்றம் தில்க்ஷ கோடரி Today - Breaking & Trending Today

Telix to Present at the 2021 Jefferies Virtual Healthcare

About
Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s lead investigational product, Illuccix
® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, ....

United States , Stewart Holmstrom , Christian Behrenbruch , Telix Pharmaceuticals , Telix Corporate Communications , Australian Securities Exchange , Australian Therapeutic Goods Administration , European Union , Corporate Communications , Telix Pharmaceuticals Limited , Pharmaceuticals Limited , Chief Executive Officer , Jefferies Virtual Healthcare Conference , Molecularly Targeted Radiation , Australian Stock Exchange Tlx Ax , Telix Pharmaceuticals Limited , Christian Behrenbruch , Efferies Healthcare 2021 , Telix Pharmaceuticals , New York , ஒன்றுபட்டது மாநிலங்களில் , ஆஸ்திரேலிய பத்திரங்கள் பரிமாற்றம் , ஐரோப்பிய தொழிற்சங்கம் , பெருநிறுவன தகவல்தொடர்புகள் , மருந்துகள் வரையறுக்கப்பட்டவை , தலைமை நிர்வாகி அதிகாரி ,

First Patient Dosed in Japanese Prostate Cancer Imaging

First Patient Dosed in Japanese Prostate Cancer Imaging Study
May 24, 2021 21:04 ET
| Source:
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited
North Melbourne, AUSTRALIA
MELBOURNE, Australia and KYOTO, Japan, May 25, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product TLX591-CDx (Illuccix
®, Kit for the preparation of
68Ga-PSMA-11 injection). The study is an academic collaboration between Telix and Kanazawa University.
The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan. The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of T ....

United States , Cdx Illuccix , Shintaro Nishimura , Stewart Holmstrom , Christian Behrenbruch , Kanazawa Advanced Medical Center Kadmedic , Telix Pharmaceuticals , Kanazawa University , Australian Securities Exchange , Innovative Clinical Research Center , Australian Therapeutic Goods Administration , European Union , Corporate Communications , Telix Pharmaceuticals Limited , Nuclear Medicine At Kanazawa University Hospital , Kanazawa University Hospital , Pharmaceuticals Limited , Principal Investigator , Professor Mizokami , Professor Murayama , Professor Kinuya , Nuclear Medicine , Kanazawa Advanced Medical Center , Japan President , Molecularly Targeted Radiation , Australian Stock Exchange Tlx Ax ,

Czech Republic First European Country to Grant National Authorisation for the Use of Telix's Prostate Cancer Imaging Product Australian Stock Exchange:TLX.AX

Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
February 16, 2021 01:05 ET
| Source:
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited
North Melbourne, AUSTRALIA
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the Czech Republic is the first European health authority to grant a national authorisation allowing the use of TLX591-CDx (Kit for the preparation of
68Ga-PSMA-11), a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA) for the imaging of prostate cancer using Positron Emission Tomography (PET). ....

United States , New Zealand , Czech Republic , Stewart Holmstrom , David Zogala , Christian Behrenbruch , Telix Pharmaceuticals , Czech Ministry Of Health , Nuclear Medicine Institute , University Hospital Prague , Australian Securities Exchange , Czech Society Of Nuclear Medicine , Treatment Programme , European Union , Corporate Communications , Telix Pharmaceuticals Limited , Ministry Of Health The Czech Republic , Therapeutic Goods Administration , Therapeutic Programme , Pharmaceuticals Limited , Prostate Specific Membrane Antigen , Positron Emission Tomography , Specific Therapeutic Programme , Czech Society , Nuclear Medicine , General University Hospital Prague ,